Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLNN OTCMKTS:ETST NASDAQ:JMAC NYSEMKT:PHGE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLNNClene$6.47-2.0%$4.34$2.28▼$7.10$64.89M0.5877,417 shs97,183 shsETSTEarth Science Tech$0.20+7.4%$0.19$0.00▼$0.25$58.86M1.91101,541 shs26,024 shsJMACMaxpro Capital Acquisition$5.75+5.9%$5.77$7.50▼$19.22$77.21M0.0174,040 shs44,675 shsPHGEBiomX$0.46-37.5%$0.48$0.34▼$2.40$13.73M1.39347,190 shs53,300 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLNNClene-0.45%+3.29%+79.35%+57.14%+14.78%ETSTEarth Science Tech-3.37%+5.80%-4.51%+29.31%+16.38%JMACMaxpro Capital Acquisition+5.18%+38.03%-4.37%-16.51%-49.80%PHGEBiomX-3.78%-11.19%+1.47%+10.50%-56.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLNNClene$6.47-2.0%$4.34$2.28▼$7.10$64.89M0.5877,417 shs97,183 shsETSTEarth Science Tech$0.20+7.4%$0.19$0.00▼$0.25$58.86M1.91101,541 shs26,024 shsJMACMaxpro Capital Acquisition$5.75+5.9%$5.77$7.50▼$19.22$77.21M0.0174,040 shs44,675 shsPHGEBiomX$0.46-37.5%$0.48$0.34▼$2.40$13.73M1.39347,190 shs53,300 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLNNClene-0.45%+3.29%+79.35%+57.14%+14.78%ETSTEarth Science Tech-3.37%+5.80%-4.51%+29.31%+16.38%JMACMaxpro Capital Acquisition+5.18%+38.03%-4.37%-16.51%-49.80%PHGEBiomX-3.78%-11.19%+1.47%+10.50%-56.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLNNClene 3.00Buy$32.60403.86% UpsideETSTEarth Science Tech 0.00N/AN/AN/AJMACMaxpro Capital Acquisition 0.00N/AN/AN/APHGEBiomX 3.00Buy$21.004,445.45% UpsideCurrent Analyst Ratings BreakdownLatest PHGE, JMAC, ETST, and CLNN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025CLNNCleneBenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$33.00 ➝ $31.008/21/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.008/18/2025CLNNCleneCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$83.00 ➝ $48.008/14/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.007/18/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.006/30/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLNNClene$286K226.90N/AN/A($1.06) per share-6.10ETSTEarth Science Tech$33.12M1.78$0.01 per share16.65$0.01 per share20.00JMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/APHGEBiomXN/AN/AN/AN/A$0.70 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLNNClene-$39.40M-$3.76N/AN/AN/A-10,386.36%N/A-125.49%11/12/2025 (Estimated)ETSTEarth Science Tech$3.25MN/A0.00∞N/A7.93%72.31%41.28%11/13/2025 (Estimated)JMACMaxpro Capital AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/APHGEBiomX-$28.32M-$1.36N/AN/AN/AN/A-127.82%-56.50%N/ALatest PHGE, JMAC, ETST, and CLNN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CLNNClene-$0.49-$0.78-$0.29-$0.78$0.06 million$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLNNCleneN/AN/AN/AN/AN/AETSTEarth Science TechN/AN/AN/AN/AN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/APHGEBiomXN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLNNCleneN/A1.581.57ETSTEarth Science Tech0.010.910.67JMACMaxpro Capital AcquisitionN/AN/AN/APHGEBiomX0.512.842.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLNNClene23.28%ETSTEarth Science TechN/AJMACMaxpro Capital Acquisition73.18%PHGEBiomX40.57%Insider OwnershipCompanyInsider OwnershipCLNNClene35.30%ETSTEarth Science Tech24.90%JMACMaxpro Capital Acquisition19.27%PHGEBiomX3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLNNClene10010.03 million6.46 millionOptionableETSTEarth Science Tech3294.30 million221.02 millionNot OptionableJMACMaxpro Capital Acquisition2,02113.43 million10.84 millionNot OptionablePHGEBiomX12026.56 million44.04 millionNot OptionablePHGE, JMAC, ETST, and CLNN HeadlinesRecent News About These CompaniesBiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 4, 2025 | finance.yahoo.comBiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic FibrosisAugust 19, 2025 | globenewswire.comBiomX Posts Q2 Loss With 14% Cost DropAugust 14, 2025 | aol.comABiomX Inc. (PHGE) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | seekingalpha.comBiomX Reports Second Quarter 2025 Financial Results and Provides Program UpdatesAugust 13, 2025 | globenewswire.comWhat to Expect from BiomX's EarningsAugust 12, 2025 | benzinga.comBiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025August 6, 2025 | globenewswire.comBiomX stock soars after initiating Phase 2b trial for cystic fibrosis therapyJuly 14, 2025 | investing.comBiomX Shares Surge 60% Following Start of Phase 2b Trial for Cystic Fibrosis TreatmentJuly 14, 2025 | msn.comPHGE | BiomX Inc. Stock Overview (U.S.: NYSE American) | Barron'sJuly 14, 2025 | barrons.comBiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic FibrosisJuly 14, 2025 | globenewswire.comBiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic FibrosisJuly 8, 2025 | globenewswire.comBiomX Inc. to Present Positive Phase 2 Results for BX211 at Biomed Israel 2025 ConferenceMay 21, 2025 | nasdaq.comBiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 ConferenceMay 19, 2025 | globenewswire.comBiomX Inc. (AMEX:PHGE) Q1 2025 Earnings Call TranscriptMay 17, 2025 | msn.comBiomX Inc. (PHGE) Q1 2025 Earnings Conference Call TranscriptMay 15, 2025 | seekingalpha.comBiomX Reports First Quarter 2025 Financial Results and Provides Business and Program UpdatesMay 15, 2025 | globenewswire.comBiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025May 8, 2025 | globenewswire.comBiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowApril 18, 2025 | zacks.comBiomX announces going concern qualification from independent auditApril 1, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHGE, JMAC, ETST, and CLNN Company DescriptionsClene NASDAQ:CLNN$6.47 -0.13 (-1.97%) Closing price 04:00 PM EasternExtended Trading$6.44 -0.02 (-0.39%) As of 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Earth Science Tech OTCMKTS:ETST$0.20 +0.01 (+7.41%) As of 11:22 AM EasternEarth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida.Maxpro Capital Acquisition NASDAQ:JMAC$5.75 +0.32 (+5.95%) As of 09/9/2025Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.BiomX NYSEMKT:PHGE$0.46 -0.28 (-37.48%) Closing price 03:58 PM EasternExtended Trading$0.46 +0.00 (+0.22%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
